Clinical Trial Update: Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating injection site tolerability, safety, pharmacokinetics and pharmacodynamics of different single-dose regimens of Alirocumab (SAR2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Alirocumab (Praluent) (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED